Saturday, 03 April 2021 10:17

Anticoagulation news items. Week commencing 29th March 2021

Relative risk of arterial and venous thromboembolism in persons with cancer vs. persons without cancer—a nationwide analysis

European Heart Journal
Austrian analysis (2006–07; n = 8,306,244) found strong association between cancer and arterial thromboembolism (RR 6.88; 95% CI 4.81–9.84) and venous thromboembolism (14.91; 8.90–24.95) and support concept of shared risk factors and pathobiology between these diseases.


Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation: A Population-Based Cohort Study

Annals of Internal Medicine
In this retrospective American study (n= 56,336), patients with valvular AF who were new users of DOACs had lower risks for ischaemic stroke or systemic embolism (HR 0.64 [95%CI, 0.59-0.70]) and major bleeding events (HR 0.67 [CI 0.63-0.72]) vs new users of warfarin.


Thromboembolism and the Oxford–AstraZeneca COVID-19 vaccine: side-effect or coincidence?

The Lancet
Danish registry study (n=4, 915 ,426, 9 years of data) suggests that the reported number of thromboembolic events with the AZ vaccine does not seem to be increased vs incidence rates from the entire Danish population before the introduction of the vaccination programme.


AstraZeneca COVID-19 vaccine: review of very rare cases of unusual blood clots continues

European Medicines Agency
EMA's safety committee has met to discuss ongoing review of very rare cases of unusual blood clots linked to low numbers of platelets, in people vaccinated with AZ's COVID-19 vaccine (now called Vaxzevria). At present, no specific risk factors or causal link have been identified.



The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at: